Literature DB >> 14592911

Standards of measurements in myasthenia gravis.

Richard J Barohn1.   

Abstract

In 1997, the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America formed a Task Force to develop classification and outcome measures for myasthenia gravis (MG). The goal of the Task Force was to achieve uniformity in recording and reporting clinical trials and outcomes research. The Task Force met frequently over a three-year period, obtained input from national and international experts, and produced a consensus document on recommendations for MG clinical research standards. In this article, the essential elements of the Task Force's recommendations will be summarized. In addition, several other MG measurement tools that are in various stages of development are mentioned.

Entities:  

Mesh:

Year:  2003        PMID: 14592911     DOI: 10.1196/annals.1254.056

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

2.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

3.  Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients.

Authors:  David Cioncoloni; Stefania Casali; Federica Ginanneschi; Marisa Carone; Boni Veronica; Alessandro Rossi; Fabio Giannini
Journal:  Neurol Sci       Date:  2016-04-01       Impact factor: 3.307

4.  Significance of B10 cell in patients with thymoma complicated with myasthenia gravis.

Authors:  Yang Lu; Fanjie Meng; Yang Yang; Lan Li; Donghao Wang; Yuantao Cui; Shangwen Dong; Wanhua Wang
Journal:  Oncotarget       Date:  2017-05-17

5.  A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus.

Authors:  Michael Schroeter; Benjamin Berger; Franz Blaes; Tim Hagenacker; Sebastian Jander; Julia Kaiser; Petra Kalischewski; De-Hyung Lee; Tobias Ruck; Ulrike Schara; Peter Urban; Andreas Meisel
Journal:  J Cent Nerv Syst Dis       Date:  2021-02-01

6.  May positron emission tomography reveal ectopic or active thymus in preoperative evaluation of non-thymomatous myasthenia gravis?

Authors:  Tommaso Claudio Mineo; Vincenzo Ambrogi; Orazio Schillaci
Journal:  J Cardiothorac Surg       Date:  2014-09-05       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.